Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9832 | 0.97 | MEN1 (0.33) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Ammonia Solution, Strong SCHEMBL19410117 | 0.94 | MEN1 (0.32) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Hydrochloric Acid SCHEMBL25183519 | 0.90 | CXCR4 (0.30) | — | |
| Pyrrolidine SCHEMBL18817855 | 0.89 | ALDH1A1 (0.40) | — | |
| SCHEMBL1222103 | 0.87 | CXCR4 (0.32) | — | |
| SCHEMBL213822 | 0.86 | MEN1 (0.30) | MEN1KMT2AKDM4EGAACYP2C9 | |
| SCHEMBL7167876 | 0.83 | ALDH1A1 (0.41) | — | |
| SCHEMBL824614 | 0.80 | — | — | |
| SCHEMBL23310445 | 0.80 | CXCR4 (0.35) | MEN1KMT2AKDM4EGAACYP2C9 | |
| SCHEMBL22607230 | 0.79 | CXCR4 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016079757-A2 | NOVEL PROCESSES FOR PREPARING 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | SYMED LABS LIMITED (IN) | 2016-05-26 | — | — | WO | claimed |
| CN-112442050-B | RET inhibitor, pharmaceutical composition and application thereof | 广东东阳光药业股份有限公司 | 2024-08-09 | — | — | CN | disclosed |
| EP-4086245-A1 | PROCESSES FOR PREPARING INTERMEDIATES FOR THE SYNTHESIS OF A JAK INHIBITOR | Incyte Corporation (US) | 2022-11-09 | — | — | EP | disclosed |
| EP-3985008-A1 | PROCESSES AND INTERMEDIATES FOR MAKING A JAK INHIBITOR | Incyte Holdings Corporation (US) | 2022-04-20 | — | — | EP | disclosed |
| EP-3489239-B1 | PROCESSES AND INTERMEDIATES FOR MAKING A JAK INHIBITOR | INCYTE HOLDINGS CORP (US) | 2021-09-15 | — | — | EP | disclosed |
| US-10968218-B2 | Tetrahydropyridopyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2021-04-06 | — | — | US | disclosed |
| WO-2021043209-A1 | RET INHIBITOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 广东东阳光药业有限公司 | 2021-03-11 | — | — | WO | disclosed |
| US-10899736-B2 | Processes and intermediates for making a JAK inhibitor | INCYTE CORPORATION (US) | 2021-01-26 | — | — | US | disclosed |
| EP-3746429-A1 | PROCESSES FOR PREPARING (1 -(3-FLUORO-2-(TRIFLUOROMETHYL)ISONICOTINYL)PIPERIDINE-4-ONE) | Incyte Corporation (US) | 2020-12-09 | — | — | EP | disclosed |
| EP-3240537-B1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINES AND TETRAHYDROPYRIDOPYRIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2020-09-09 | — | — | EP | disclosed |
| US-20140256941-A1 | PROCESSES AND INTERMEDIATES FOR MAKING A JAK INHIBITOR | INCYTE CORPORATION (US) | 2014-09-11 | — | — | US | disclosed |
| US-8592463-B2 | Hedgehog pathway antagonists and therapeutic applications thereof | SIENA BIOTECH S.P.A. (IT) | 2013-11-26 | — | — | US | disclosed |
| US-20130060026-A1 | PROCESSES AND INTERMEDIATES FOR MAKING A JAK INHIBITOR | INCYTE CORPORATION (US) | 2013-03-07 | — | — | US | disclosed |
| US-20100286114-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SIENA BIOTECH S.P.A. (IT) | 2010-11-11 | — | — | US | disclosed |
| EP-2227456-A2 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | Siena Biotech S.p.A. (IT) | 2010-09-15 | — | — | EP | disclosed |
| WO-2009074300-A2 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SIENA BIOTECH S.P.A. (IT) | 2009-06-18 | — | — | WO | disclosed |
| US-6423725-B1 | ANALGESICS | PFIZER INC | 2002-07-23 | — | — | US | disclosed |
| EP-1049689-B1 | 4-(2-KETO-1-BENZIMIDAZOLINYL)PIPERIDINE COMPOUNDS AS ORL1-RECEPTOR AGONISTS | PFIZER (US) | 2002-06-26 | — | — | EP | disclosed |
| EP-1049689-A1 | 4-(2-KETO-1-BENZIMIDAZOLINYL)PIPERIDINE COMPOUNDS AS ORL1-RECEPTOR AGONISTS | PFIZER INC. (US) | 2000-11-08 | — | — | EP | disclosed |
| WO-1999036421-A1 | 4-(2-KETO-1-BENZIMIDAZOLINYL)PIPERIDINE COMPOUNDS AS ORL1-RECEPTOR AGONISTS | PFIZER PHARMACEUTICALS INC. (JP) | 1999-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10899736-B2 | Processes and intermediates for making a JAK inhibitor | JAK1, JAK2, JAK3 | GAA 4027/4885MEN1 1782/4885KMT2A 663/4885 |
| US-20140256941-A1 | PROCESSES AND INTERMEDIATES FOR MAKING A JAK INHIBITOR | JAK1, JAK2, JAK3 | GAA 4027/4885MEN1 1782/4885KMT2A 663/4885 |
| US-20130060026-A1 | PROCESSES AND INTERMEDIATES FOR MAKING A JAK INHIBITOR | JAK1, JAK2, JAK3 | GAA 4027/4885MEN1 1782/4885KMT2A 663/4885 |
| US-20100286114-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SHH, GLI1, SMO | GAA 2515/4885MEN1 3442/4885KMT2A 3040/4885 |
| US-10968218-B2 | Tetrahydropyridopyrimidines for the treatment and prophylaxis of hepatitis B virus infection | DPYD, TPMT, TYMP | GAA 4072/4885MEN1 2314/4885KMT2A 2506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.